semaglutide and kidney failure Cardio-kidney-metabolic protective effects of across the spectrum of chronic disease Semaglutide in chronic kidney disease

Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy

PrimeHealthMDs providers guide patients through the entire process, helping them understand how semaglutide works, what to expect throughout treatment, and how to support long-term metabolic health

That communication becomes quieter, slower, and less precise with age

And an interim analysis of a phase II Study of the glutaminase inhibitor CB-839 in combination with Azacitidine in advanced myelodysplastic syndrome (MDS) showed CB-839 at a dose of 600 mg BID orally continuously daily is safe and well tolerated in combination with azacitidine in patients with advanced MDS with an acceptable safety profile [92]

Exhibit 03 Strategic routes to GLP-1 category leadership Three routes to market, mapped against speed of deployment and depth of scientific differentiation

A.AfzaliM